Approval For Orally Disintegrating Formulation Of Amlodin, Hypertension/Angina Pectoris Treatment, Japan

Main Category: Hypertension
Also Included In: Cardiovascular / Cardiology
Article Date: 22 Mar 2006 - 0:00 PDT

email to a friend

printer friendly

opinions

Current Article Ratings:

Patient / Public:		5 (1 votes)
Healthcare Prof:		2.5 (2 votes)

Tokyo, (JCN) - Dainippon Sumitomo Pharma announced on March 17 that it has received approval for its proprietary ethical drugs, Amlodin OD Tablet 2.5mg/ 5mg, from the Ministry of Health, Labor and Welfare as of March 15.

Produced using the company's proprietary formulation technology SUITAB, the orally disintegrating tablets are a calcium antagonist indicated for the treatment of hypertension and angina pectoris.

The company will put on sale the product after the National Health Insurance listing. Amlodin has been widely prescribed in Japan since its release in 1993.

By Aki Tsukioka, JCN Staff Writer

Company Profile

� 2001-2006 The Japan Corporate News Network (JCN) K.K.

Additional
References
Citations

Article adapted by Medical News Today from original press release.
Visit our hypertension section for the latest news on this subject.

There are no references listed for this article.

Please use one of the following formats to cite this article in your essay, paper or report:

MLA

Kieth Hadsmith. "Approval For Orally Disintegrating Formulation Of Amlodin, Hypertension/Angina Pectoris Treatment, Japan." Medical News Today. MediLexicon, Intl., 22 Mar. 2006. Web.
16 Feb. 2012. <http://www.medicalnewstoday.com/releases/39972.php>

APA

Kieth Hadsmith. (2006, March 22). "Approval For Orally Disintegrating Formulation Of Amlodin, Hypertension/Angina Pectoris Treatment, Japan." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/39972.php.

Please note: If no author information is provided, the source is cited instead.

Rate this article:
(Hover over the stars then click to rate)

Patient / Public:

Health Professional:

Add Your Opinion

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

Hypertension

Follow Our Hypertension News On Twitter

Get the latest news for this category delivered straight to your Twitter account. Simply visit our Hypertension Twitter account and select the 'follow' option.

Conditions Information

View list of all 'What Is...' articles »

Your Name:*
E-mail Address:*
Title For Opinion:*
Opinion:*

This is to help prevent SPAM submissions. Please enter the words exactly as they appear, including capital letters and punctuation.*

Approval For Orally Disintegrating Formulation Of Amlodin, Hypertension/Angina Pectoris Treatment, Japan

Add Your Opinion

Hypertension

Most Popular Articles

Follow Our Hypertension News On Twitter

Conditions Information